Home  |  Contact

UniProtKB/Swiss-Prot Q9UQ90: Variant p.Arg486Gln

Paraplegin
Gene: SPG7
Variant information

Variant position:  486
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Glutamine (Q) at position 486 (R486Q, p.Arg486Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  486
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  795
The length of the canonical sequence.

Location on the sequence:   MRPGRLDRHVFIDLPTLQER  R EIFEQHLKSLKLTQSSTFYS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MRPGRLDRHVFIDLPTLQERREIFEQHLKSLKLTQSSTFYS

Mouse                         MRPGRLDRHVFIDLPTLQERREIFEQHLKGLKLTQPSSFYS

Rat                           MRPGRLDRHVFIDLPTLQERREIFEQHLKGLKLTQPSSFYS

Slime mold                    --------------------QDAFDS------WTYDNIIYT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 106 – 795 Paraplegin
Topological domain 270 – 795 Mitochondrial matrix
Binding site 492 – 492 ATP
Modified residue 505 – 505 3'-nitrotyrosine
Alternative sequence 443 – 489 MGTTDHVIVLASTNRADILDGALMRPGRLDRHVFIDLPTLQERREIF -> ASLDQLPSQGTMRKLRGKTPACSCLTEPTGSRRAMEGHSLCWGCLLH. In isoform 2.
Helix 482 – 495


Literature citations

Mutation analysis of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia.
Elleuch N.; Depienne C.; Benomar A.; Hernandez A.M.; Ferrer X.; Fontaine B.; Grid D.; Tallaksen C.M.E.; Zemmouri R.; Stevanin G.; Durr A.; Brice A.;
Neurology 66:654-659(2006)
Cited for: VARIANTS SPG7 VAL-510 AND VAL-581 DEL; VARIANTS THR-2; GLN-82 DEL; PRO-284; HIS-294; GLN-486 ALA-503; LEU-545; THR-603; LEU-635; THR-645; HIS-650; GLN-688 AND ASP-730;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.